CAR T-cell Therapy Meets Clonal Hematopoiesis
Overview
Authors
Affiliations
Clonal hematopoiesis of indeterminate potential (CHIP) is common in patients with hematologic malignancies. Recent publications provide evidence that CHIP may affect chimeric antigen receptor T-cell therapy efficacy and that the incidence of treatment-related toxicities such as cytokine release syndrome and immune effector-cell associated neurotoxicity syndrome may be affected. See related article by Saini et al., p. 385 (8).
The emerging role of clonal haematopoiesis in the pathogenesis of dilated cardiomyopathy.
Verdonschot J, Fuster J, Walsh K, Heymans S Eur Heart J. 2024; .
PMID: 39417710 PMC: 11638724. DOI: 10.1093/eurheartj/ehae682.
Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis.
Reinhardt B, Lee P, Sasine J Cells. 2023; 12(4).
PMID: 36831198 PMC: 9954220. DOI: 10.3390/cells12040531.
Eder L, Martinovic D, Mazzeo P, Ganster C, Hasenkamp J, Thomson J Curr Oncol. 2023; 30(1):1146-1150.
PMID: 36661736 PMC: 9858310. DOI: 10.3390/curroncol30010087.